Loading market data...
Mon, 26 Oct 2026
06:56:18 pm
Mon, 26 Oct 2026
06:56:18 pm
Rudransh Sangwan
Published at: July 28, 2026, 9:53 AM
Synopsis
Manipal Health Enterprises IPO opens on July 29 with a ₹9,275.22 crore public issue at a price band of ₹560–₹590. Check GMP, subscription dates, lot size, financials, valuation, risks, key strengths, and whether investors should apply.
India's primary market is preparing for one of the largest healthcare public issues of the year as a leading hospital operator launches a ₹9,275.22 crore Initial Public Offering (IPO). The issue has generated significant interest among institutional and retail investors because of the company's nationwide hospital network, consistent expansion strategy, improving operating performance and strong position in India's rapidly growing healthcare industry.
The public issue comes at a time when India's healthcare sector continues benefiting from rising insurance penetration, increasing demand for quality medical infrastructure, higher healthcare spending and growing medical tourism. The company also plans to utilise a major portion of the IPO proceeds to reduce debt, strengthening its balance sheet and creating room for future expansion across hospitals, specialty healthcare services and acquisitions.
While the business enjoys strong fundamentals and one of the largest private hospital networks in the country, investors are also evaluating the IPO's valuation, grey market premium, profitability trends and long-term growth prospects before making their investment decisions.
| Particulars | Details |
|---|---|
| IPO Size | ₹9,275.22 Crore |
| Issue Type | Book Built Issue |
| Fresh Issue | ₹8,000 Crore |
| Offer For Sale | ₹1,275.22 Crore |
| Face Value | ₹2 Per Share |
| Exchange | NSE & BSE |
| Registrar | KFin Technologies |
| Event | Date |
|---|---|
| IPO Opens | 29 July 2026 |
| IPO Closes | 31 July 2026 |
| Basis of Allotment | 3 August 2026 |
| Refund Initiation | 4 August 2026 |
| Shares Credited | 4 August 2026 |
| Tentative Listing | 5 August 2026 |
The IPO has been priced between ₹560 and ₹590 per equity share. Investors can apply for a minimum of 25 shares, translating into a minimum investment of ₹14,750 at the upper price band. Retail investors can bid for up to 13 lots, while separate application limits apply for Small HNI and Big HNI investors.
| Particulars | Details |
|---|---|
| Price Band | ₹560–₹590 |
| Lot Size | 25 Shares |
| Minimum Investment | ₹14,750 |
| Retail Maximum | 13 Lots |
| sNII Minimum | 14 Lots |
| bNII Minimum | 68 Lots |
The IPO consists of a combination of fresh equity issuance and an offer for sale by existing shareholders. A larger fresh issue indicates that most of the capital raised will be utilised for strengthening the company's financial position rather than providing an exit to existing investors.
| Component | Amount |
|---|---|
| Fresh Issue | ₹8,000 Crore |
| Offer For Sale | ₹1,275.22 Crore |
| Total IPO Size | ₹9,275.22 Crore |
A significant portion of the fresh capital will be used to reduce outstanding borrowings, helping lower finance costs and improve the balance sheet. The company will also utilise part of the proceeds to acquire the remaining minority stake in one of its subsidiaries, while the balance will be used for general corporate purposes and future expansion initiatives.
| Purpose | Amount |
|---|---|
| Debt Repayment | ₹5,552.76 Crore |
| Acquisition of Minority Stake | ₹574 Crore |
| General Corporate Purposes | Remaining Amount |
The company has established itself as one of India's largest integrated healthcare providers, operating a diversified network of multi-speciality hospitals, day-care centres and outpatient clinics across several states. Its portfolio covers advanced tertiary and quaternary healthcare services, including cardiology, oncology, neurosciences, orthopaedics, organ transplantation, emergency medicine and critical care.
The business has expanded consistently through a combination of greenfield projects, acquisitions and capacity additions. Its diversified geographical presence reduces dependence on any single market while enabling it to benefit from rising healthcare demand across both metropolitan and emerging cities. Increasing health insurance coverage, higher disposable incomes and greater awareness of quality healthcare continue to support long-term growth opportunities for organised hospital operators.
| Particulars | Value |
|---|---|
| Hospitals | 49 |
| Licensed Beds | 13,037 |
| Clinics | 21 |
| Employees | 24,240+ |
The business has delivered healthy revenue growth over the past year as patient volumes improved and recently acquired hospitals contributed to operations. Total income increased to ₹10,520.52 crore during FY26 from ₹8,362.79 crore a year earlier, reflecting strong operational momentum across its healthcare network.
Although revenue continued growing, profit after tax moderated due to higher operating costs associated with expansion, acquisitions and capacity enhancement. Operating profitability remained healthy, with EBITDA increasing substantially, indicating that the core healthcare business continues to generate strong cash flows despite higher investments.
| Metric | FY26 | FY25 |
|---|---|---|
| Total Income | ₹10,520.52 Crore | ₹8,362.79 Crore |
| EBITDA | ₹2,795.94 Crore | ₹2,247.07 Crore |
| Profit After Tax | ₹916.52 Crore | ₹1,081.67 Crore |
| Net Worth | ₹8,440.92 Crore | ₹5,865.66 Crore |
| Ratio | Value |
|---|---|
| Return on Net Worth (RoNW) | 10.57% |
| EBITDA Margin | 26.6% |
| Net Asset Value Per Share | ₹72.55 |
| Book Value | ₹72.55 |
The IPO has been trading at a modest premium in the grey market ahead of subscription. The latest Grey Market Premium suggests cautious optimism among investors rather than expectations of a very large listing gain. Investors should remember that GMP is unofficial and should not be the sole basis for an investment decision.
| Metric | Value |
|---|---|
| Latest GMP | ₹9 |
| Upper Price Band | ₹590 |
| Estimated Listing Price | ₹599 |
| Estimated Listing Premium | 1.53% |
The business enjoys several structural advantages that position it well for long-term growth. It operates one of India's largest hospital networks with a diversified presence across multiple cities, reducing geographical concentration risk. The company also benefits from a recognised healthcare brand, a wide range of specialised medical services, experienced healthcare professionals and a growing presence in high-margin tertiary care.
India's healthcare sector continues to benefit from increasing medical tourism, higher insurance penetration, ageing demographics, rising lifestyle diseases and greater healthcare awareness. These long-term industry drivers are expected to support sustained demand for organised private hospital operators over the coming years.
Despite its strong market position, investors should also evaluate certain risks before applying for the IPO. The company continues to operate in a capital-intensive industry where hospital expansion requires significant investment and longer gestation periods. Although the IPO will substantially reduce debt, profitability could remain influenced by operating costs, occupancy levels, integration of acquired hospitals and future capital expenditure.
Valuation is another important consideration. Healthcare businesses with established brands generally command premium valuations because of their predictable cash flows and long-term growth potential. Investors should therefore evaluate whether the current pricing adequately reflects future earnings growth and expansion opportunities.
The IPO offers exposure to one of India's fastest-growing healthcare companies operating in an industry supported by favourable long-term structural trends. The planned debt reduction is expected to strengthen the balance sheet, while the company's extensive hospital network and consistent expansion strategy provide a solid platform for future growth.
Long-term investors seeking exposure to India's healthcare sector may find the business attractive because of its scale, diversified operations and improving financial profile. Investors looking purely for listing gains should closely monitor subscription demand, institutional participation and grey market trends before making a decision.
Manipal Health Enterprises IPO is a ₹9,275.22 crore public issue opening on 29 July 2026 with a price band of ₹560–₹590 per share. The issue includes an ₹8,000 crore fresh issue and an ₹1,275.22 crore offer for sale, with a significant portion of the proceeds earmarked for debt reduction and strengthening the company's balance sheet.
The company operates 49 hospitals, 13,037 licensed beds and 21 clinics, making it one of India's largest private healthcare providers. Healthy revenue growth, expanding healthcare demand and strong industry fundamentals support its long-term outlook, although investors should carefully evaluate valuation, profitability trends and listing expectations before applying.
The Manipal Health Enterprises IPO will open for subscription on 29 July 2026 and close on 31 July 2026.
The Manipal Health Enterprises IPO has a price band of ₹560 to ₹590 per equity share.
Retail investors need to apply for one lot of 25 shares, requiring a minimum investment of ₹14,750 at the upper price band.
The company plans to utilise the IPO proceeds primarily for repayment of borrowings, acquiring a minority stake in a subsidiary, and general corporate purposes, helping strengthen its balance sheet and support future expansion.
The latest Grey Market Premium (GMP) for the Manipal Health Enterprises IPO is around ₹9 per share, indicating a modest premium over the upper price band. As GMP is unofficial, it should not be considered a guarantee of listing performance.
The lot size for the Manipal Health Enterprises IPO is 25 equity shares, with additional applications required in multiples of 25 shares.
The shares of Manipal Health Enterprises are expected to be listed on the NSE and BSE on 5 August 2026, subject to the completion of the IPO process.
The IPO offers exposure to one of India's largest private healthcare providers with a strong hospital network and long-term growth opportunities. Investors should evaluate the company's financial performance, valuation, industry outlook and their own investment objectives before making an investment decision.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Jio Platforms IPO worth Rs 30,213 crore was fully subscribed 1.01 times early on Day 1. Check category wise bids, price band and key IPO dates.
Jio Platforms IPO draws nearly Rs 2.5 lakh crore in reported investor demand. LIC, global funds and top mutual fund houses are among interested...
Jio Platforms IPO may value the company at Rs 10.3 lakh crore, with 2.9% equity on offer. See why fund managers view Jio alongside Airtel.
